Loading...
Loading...
- Inari Medical Inc's NARI Q1 revenue was $86.8 million, up 4% sequentially and 51% Y/Y, beating the consensus of $83.61 million.
- The increase over the prior year was driven by continued U.S. commercial expansion and new product introductions.
- The gross margin was 88.5% compared to 91.9% a year ago, modestly lower primarily due to the move to its larger production facility in Q4 FY21.
- Operating expenses reached $79.9 million, compared to $45.1 million, mainly driven by personnel-related expenses on increased headcount to fund the commercial expansion, R&D, and clinical and support organizations.
- Inari posted a Q1 EPS loss of $(0.06), a turnaround from $0.13 a year ago and beating the consensus of $(0.09).
- The company treated 8,800 patients, up 14% sequentially.
- Cash, cash equivalents, and short-term investments were $338.7 million.
- Guidance: Inari Medical expects FY22 sales of $360 million - $370 million, up from prior guidance of $350 million - $360 million, above the consensus of $356.69 million.
- Price Action: NARI shares traded lower by 5% at $79.18 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in